Vaxart Inc (VXRT)
Vaxart, Inc. is a clinical-stage biotechnology company listed on OTC Markets under the symbol VXRT. The company is developing oral recombinant protein vaccines using its proprietary oral vaccine platform, which combines vector, adjuvant, and antigen components. Its pipeline includes a Phase 2 bivalent oral tablet vaccine for norovirus strains GI.1 and GII.4, a Phase 2 coronavirus vaccine for SARS-CoV-2, and a Phase 2 seasonal influenza vaccine for H1 influenza. Vaxart is also advancing a preclinical human papillomavirus therapeutic vaccine targeting HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. In addition, the company has a licensing agreement with Altesa Biosciences to develop and commercialize Vapendavir, a broad-spectrum antiviral. Vaxart is headquartered in South San Francisco, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-VXRT
|
$0.61
|
18.8% Upside
|
Undervalued
|
$3.33
|
553.7% Upside
|
Bargain
|
Great
|
—
|
—
|
—
|
0.0%
|
July 30, 2026
|
3.3x
|
1.3x
|
0.5x
|
120.6 M
|
71.825 M
|
9.2%
|
98.5%
|
-0.3
|
—
|
39.9%
|
